Opinion

Video

Beyond HER2: Expanding the Biomarker Testing Landscape in Metastatic Breast Cancer

Author(s):

Heather Moore, BCOP, CPP, PharmD, Jodi Taraba, PharmD, MS, BCOP

Panelists discuss how HER2 testing optimization requires multisite sampling and quantitative assessment methods to account for intratumoral heterogeneity. Beyond HER2, biomarkers such as PI3K mutations, hormone receptor status, and tumor mutational burden can guide therapy selection for metastatic breast cancer (mBC), enabling more personalized treatment approaches.

Video content above has been prompted by the following:

  • How can we optimize HER2 testing and antibody-drug conjugate treatment selection considering tumor heterogeneity across different cancer sites?
  • Are there additional biomarkers beyond HER2 that can help guide mBC therapy selection?
Related Videos
5 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
Related Content
Focusing Treatment on Multiple Pathways to Reduce Resistance and Improve Outcomes in Triple-Positive Breast Cancer
February 19th 2025

Focusing Treatment on Multiple Pathways to Reduce Resistance and Improve Outcomes in Triple-Positive Breast Cancer

Catherine A. Koivisto, RPh
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
Genetic Diversity in African Populations Can Advance Precision Medicine Globally
February 8th 2025

Genetic Diversity in African Populations Can Advance Precision Medicine Globally

Alana Hippensteele, Lead Editor
Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer
October 28th 2024

Pharmacy Focus: Oncology Edition- Exploring Pelareorep: A Novel Immunotherapy for Advanced Breast Cancer

3D rendering of brain with a tumor | Image Credit: © iDoPixBox - stock.adobe.com
February 6th 2025

Sacituzumab Govitecan Shows Potential in Overcoming Barriers to Brain Tumor Treatment in Patients With Breast Cancer

Alexandra Gerlach, Associate Editor
Topical Drug Delivery May Offer Welcome Alternatives for Breast Cancer Treatment
February 3rd 2025

Topical Drug Delivery May Offer Welcome Alternatives for Breast Cancer Treatment

Catherine A. Koivisto, RPh